SCHEMBL644549

SCHEMBL644549

COC(=O)c1cc(OC)c(Br)c(OC)c1OC

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.56
POLB P06746 2/20 0.56
PTPN1 P18031 2/20 0.53
HSD17B10 Q99714 2/20 0.51
USP2 O75604 1/20 0.51
ALDH1A1 P00352 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
HPGD P15428 2/20 0.49
GAA P10253 3/20 0.48
MAPT P10636 2/20 0.46
RAB9A P51151 1/20 0.46
LCK P06239 1/20 0.44
FYN P06241 1/20 0.44
NPSR1 Q6W5P4 2/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21635979 0.86 KDM4E (0.65) KDM4EPOLBPTPN1HSD17B10USP2
SCHEMBL23412396 0.80 PKM (0.57) KDM4EPOLBPTPN1HSD17B10USP2
SCHEMBL2113203 0.79 KDM4E (0.53) KDM4EPOLBPTPN1HSD17B10USP2
SCHEMBL5658273 0.79 KDM4E (0.57) KDM4EPOLBPTPN1HSD17B10USP2
SCHEMBL3979015 0.79 KDM4E (0.57) KDM4EPOLBPTPN1HSD17B10USP2
SCHEMBL23294024 0.79 KDM4E (0.56) KDM4EPOLBPTPN1HSD17B10USP2
SCHEMBL26660999 0.79 MAPT (0.50) KDM4EPOLBPTPN1HSD17B10USP2
SCHEMBL3709174 0.78 HSD17B10 (0.49) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL7378524 0.76 KDM4E (0.73) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL6582728 0.76 KDM4E (0.67) KDM4EPOLBHSD17B10USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-8119624-B2 Fused phenyl amido heterocyclic compounds PFIZER INC. (US) 2012-02-21 US disclosed
US-20110039821-A1 Fused Phenyl Amido Heterocyclic Compounds PFIZER INC 2011-02-17 US disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039821-A1 Fused Phenyl Amido Heterocyclic Compounds GCK, GCKR, HK1 KDM4E 1790/4885POLB 4200/4885PTPN1 2412/4885
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 KDM4E 1790/4885POLB 4200/4885PTPN1 2412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.